On February 24, 2022, the U.S. Food and Drug Administration (FDA) revised the emergency use authorization for tixagevimab co-packaged with cilgavimab (EVUSHELD™) to change the initial dose for the authorized use as pre-exposure prophylaxis of COVID-19 in certain adults and pediatric patients.
The administration side has also seen challenges, with leaders opting to invest in remote labor and rethink much of their hospital revenue cycle management staffing strategy. Some have even considered outsourcing to hospital billing services. To keep up, leaders like you will need to stay on top of how these challenges are impacting healthcare organizations and how hospital revenue cycle management solutions can step in to fill the gaps. To help you get started, here’s an overview of what you need to know about hospital revenue cycle management labor challenges today.
On February 11, the US Food and Drug Administration (FDA) authorized the emergency use of the monoclonal antibody bebtelovimab for the treatment of mild-to-moderate COVID-19 in adult and pediatric patients when all of these apply:
On December 28, the US Food and Drug Administration (FDA) revised the emergency use authorization for COVID-19 convalescent plasma with high titers of anti-SARS-CoV-2 antibodies.
